Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Equity Ratio (2020 - 2025)

Insight Molecular Diagnostics' Equity Ratio history spans 6 years, with the latest figure at 0.21 for Q3 2025.

  • For Q3 2025, Equity Ratio fell 251.34% year-over-year to 0.21; the TTM value through Sep 2025 reached 0.21, down 251.34%, while the annual FY2024 figure was 0.35, 228.02% down from the prior year.
  • Equity Ratio for Q3 2025 was 0.21 at Insight Molecular Diagnostics, down from 0.02 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.82 in Q1 2021 and bottomed at 0.35 in Q4 2024.
  • The 5-year median for Equity Ratio is 0.39 (2022), against an average of 0.32.
  • The largest annual shift saw Equity Ratio skyrocketed 33.97% in 2021 before it tumbled 251.34% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.41 in 2021, then dropped by 16.18% to 0.34 in 2022, then decreased by 20.23% to 0.27 in 2023, then crashed by 228.02% to 0.35 in 2024, then soared by 40.18% to 0.21 in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Equity Ratio are 0.21 (Q3 2025), 0.02 (Q2 2025), and 0.17 (Q1 2025).